Article

CD33 Epitope Editing Unlocks UM171-Expanded Cord Blood Grafts for AML Immunotherapy

2025-05-12

Abstract excerpt

Immunotherapies in acute myeloid leukemia (AML) are limited by shared antigen expression between leukemic and healthy hematopoietic cells, leading to on-target toxicity. Here we developed a clinically scalable strategy to engineer cord blood (CB)-derived hematopoietic stem and progenitor cell (HSPC) grafts resistant to CD33-directed therapies. Leveraging UM171-mediated expansion and adenine base editing, we precis...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 45ccabde-49f9-5d3e-b529-d934fbe6ff98
DOI: 10.1101/2025.05.07.652621

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

CD33 Epitope Editing Unlocks UM171-Expanded Cord Blood Grafts for AML ImmunotherapyDOI 10.1101/2025.05.07.652621Read

Multiplex Base Editing to Protect from CD33-Directed Therapy: Implications for Immune and Gene TherapySemantic proximity Read

Multiplex base editing to protect from CD33 directed drugs for immune and gene therapy.Semantic proximity Read

CD117 epitope-shielded hematopoietic stem cell transplantation with toxin-free conditioning and in vivo selection ameliorates a β-thalassemia modelSemantic proximity Read

CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330.Semantic proximity Read

CD33 <sup>KO</sup> -CD33-mesothelin loop CAR design avoids fratricide and improves efficacy of iNK cells against acute myeloid leukemiaSemantic proximity Read

Integrating Human Genetics and Protective Genome Editing to Enable ADGRE2-Directed AML TherapySemantic proximity Read

Genome-edited allogeneic donor “universal” chimeric antigen receptor T cellsSemantic proximity Read

CRISPR/Cas9 gene editing clarifies the role of CD33 SNP rs12459419 in gemtuzumab ozogamicin-mediated cytotoxicity.Semantic proximity Read

CD33 Splicing Polymorphism Determines Gemtuzumab Ozogamicin Response in De Novo Acute Myeloid Leukemia: Report From Randomized Phase III Children's Oncology Group Trial AAML0531.Semantic proximity Read

CD33-CD123 IF-THEN Gating Reduces Toxicity while Enhancing the Specificity and Memory Phenotype of AML-Targeting CAR-T Cells.Semantic proximity Read

Differential TIM-3 glycosylation enables specific dual targeting CAR-T therapy in acute myeloid leukemiaSemantic proximity Read

CAR-T cells with the CD38-CD73-Tim-3-HLA-DR+ phenotype predict the efficacy of tisagenlecleucel as a treatment for B cell precursor ALL.Semantic proximity Read